Unichem receives ANDA approval for quetiapine extended-release tablets
Quetiapine Extended-Release Tablets are indicated for the treatment of Schizophrenia, Bipolar disorder and adjunctive treatment of Major Depressive Disorder (MDD)
Quetiapine Extended-Release Tablets are indicated for the treatment of Schizophrenia, Bipolar disorder and adjunctive treatment of Major Depressive Disorder (MDD)
The company has reported total income of Rs. 317.45 crores during the period ended June 30, 2022
Nebivolol is used alone or together with other medicines to treat high blood pressure
Divalproex Sodium Extended-Release tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, as monotherapy and adjunctive therapy and prophylaxis of migraine headaches
The product will be commercialized from Unichem's Ghaziabad plant
It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
The company posted net profit of Rs.2.43 crores for the period ended June 30, 2020.
Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis .
Chobhe brings over 30 years of extensive experience in quality and regulatory management within the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated